Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

  • Ivana Milošević Faculty of Medicine, University of Belgrade, Serbia
  • Jaroslava Jovanović Faculty of Medicine, University of Belgrade, Serbia
  • Olja Stevanovic Faculty of Medicine, University of Belgrade, Serbia
Keywords: COVID-19, agammaglobulinemia, convalescent plasma, IL-6 inhibitor

Abstract

We present atypical course of the novel coronavirus disease (COVID-19) in 34-year man with Bruton agammaglobulinemia. The patient was successfully treated by a combination of available drugs, including convalescent plasma and interleukin-6 (IL-6) inhibitor.

Author Biographies

Ivana Milošević, Faculty of Medicine, University of Belgrade, Serbia

Ivana Milošević is Deputy Director at Clinic for infectious and Tropical Diseases, Clinical Center of Serbia in Belgrade. She is ID specialist and gastroenterohepatologist and head of Hepatology Depatment. She also teaches infectious diseases at Faculty of Medicine, University of Belgrade as associate professor. 

Jaroslava Jovanović, Faculty of Medicine, University of Belgrade, Serbia

Jaroslava Jovanović is residant at Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia, Belgrade, Serbia.

Published
2020-11-30
How to Cite
1.
Milošević I, Jovanović J, Stevanovic O (2020) Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. J Infect Dev Ctries 14:1248-1251. doi: 10.3855/jidc.13840
Section
Coronavirus Pandemic